Ameet Sarpatwari

Ameet Sarpatwari, PhD, JD

Faculty Member of the Center
Member, HMS Center for Bioethics

Ameet Sarpatwari is an Assistant Professor of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes.

Dr. Sarpatwari's work has been highly influential. His writing and resulted in multiple invitations to testify before Congress and state legislatures, to discuss proposed legislation with Hill staffers, and to be approached routinely for insight on pharmaceutical policy by reporters from such prominent news sources as the New York Times, Washington Post, and NPR.

In addition to his primary position within the Institute's division of Health Policy and Insurance Research, Dr. Sarpatwari is also a faculty member in the Center for Bioethics at Harvard Medical School, the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health ("Harvard Chan School"), and the Harvard-MIT Center for Regulatory Science. At the Harvard Chan School, he serves as the Faculty Director of the JD/MPH program and teaches a highly acclaimed class on public health law.

Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where he received a Ph.D. He subsequently studied law at the University of Maryland as a John L. Thomas Leadership Scholar. Following his legal studies, he joined the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital and Harvard Medical School as a post-doctoral fellow. He remained with PORTAL, serving as its Assistant Director for several years.

Publications View
Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices.
Authors: Authors: Sarpatwari A, Lee MP, Gagne JJ, Lu Z, Dutcher SK, Jiang W, Campbell EG, Kesselheim AS.
Clin Pharmacol Ther
View full abstract on Pubmed
Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
Authors: Authors: Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS.
Health Aff (Millwood)
View full abstract on Pubmed
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Authors: Authors: Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly J, Fischer MA, Kesselheim AS, Gagne JJ.
BMJ
View full abstract on Pubmed
Removing ERISA's Impediment to State Health Reform.
Authors: Authors: Fuse Brown EC, Sarpatwari A.
N Engl J Med
View full abstract on Pubmed
Benefits, Limitations, and Value of Abuse-Deterrent Opioids.
Authors: Authors: Curfman GD, Beletsky L, Sarpatwari A.
JAMA Intern Med
View full abstract on Pubmed
The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics.
Authors: Authors: Sarpatwari A, Gluck AR, Curfman GD.
JAMA Intern Med
View full abstract on Pubmed
Strategies That Delay Market Entry of Generic Drugs.
Authors: Authors: Vokinger KN, Kesselheim AS, Avorn J, Sarpatwari A.
JAMA Intern Med
View full abstract on Pubmed
Recalibrating Privacy Protections to Promote Patient Engagement.
Authors: Authors: Sarpatwari A, Choudhry NK.
N Engl J Med
View full abstract on Pubmed
Value-Based Pricing and State Reform of Prescription Drug Costs.
Authors: Authors: Hwang TJ, Kesselheim AS, Sarpatwari A.
JAMA
View full abstract on Pubmed
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
Authors: Authors: Kesselheim AS, Rome BN, Sarpatwari A, Avorn J.
Health Aff (Millwood)
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
General Medicine-OBC-3030, N2
1620 Tremont St
Boston, MA 02120